MedTrace Logo

HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial

NCT03832049 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1720

Last updated 2022-03-31

No results posted yet for this study

Summary

A randomized, observer-blind non-inferiority trial to evaluate alternative human papillomavirus (HPV) vaccination schedules in young females in West Africa.

Conditions

  • Human Papillomavirus Vaccine

Interventions

BIOLOGICAL

9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses

0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)

BIOLOGICAL

9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses

0.5mL intramuscular dose - 2 doses (0 and 6 months)

BIOLOGICAL

9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

0.5mL intramuscular dose - 1 doses (0 months)

Sponsors & Collaborators

Principal Investigators

  • Ed Clarke, MB ChB PhD · Medical Research Council @ LSHTM

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-14
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • The Gambia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03832049 on ClinicalTrials.gov